Orasis Pharmaceuticals - About the company
Orasis Pharmaceuticals is a series D company based in Herzliya (Israel), founded in 2015. It operates as a Developer of reformulated eye drops for the treatment of Presbyopia. Orasis Pharmaceuticals has raised $111M in funding from investors like Visionary Ventures, Sequoia Capital and Arboretum Ventures. The company has 2691 active competitors, including 905 funded and 684 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.
Company Details
Orasis Pharmaceuticals is developing reformulated eye drops for the treatment of Presbyopia. They are developing CSF-1 eye drops that assist in eliminating the use of eyeglasses. It is used as a topical solution directly to the eye which improves the elasticity of crystalline glasses. The candidate is in phase II clinical trials.
- Website
- www.orasis-pharma.com/
- Social
- Email ID
- *****@orasis-pharma.com
- Phone Number
- +972 **********
Key Metrics
Founded Year
2015
Location
Herzliya, Israel
Stage
Series D
Total Funding
$111M in 4 rounds
Latest Funding Round
Investors
Ranked
250th among 2691 active competitors
Employee Count
66 as on Sep 30, 2026
Similar Companies
Sign up to download Orasis Pharmaceuticals' company profile
Orasis Pharmaceuticals's funding and investors
Orasis Pharmaceuticals has raised a total funding of $111M over 4 rounds. Its first funding round was on Jun 05, 2018. Its latest funding round was a Venture Debt round on Oct 08, 2024 for $*****. 1 investor participated in its latest round. Orasis Pharmaceuticals has 11 institutional investors.
Here is the list of recent funding rounds of Orasis Pharmaceuticals:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 08, 2024 | 4898012 | Venture Debt | 5967065 | 5825967 | 1494231 | 1968566 |
Oct 08, 2024 | 5438526 | Series D | 3569834 | 9627947 | 3302398 | |
Sep 10, 2020 | 6896861 | Series C | 2668461 | 1323835 | 9373861 |
Access funding benchmarks and valuations. Sign up today!View details of Orasis Pharmaceuticals's funding rounds and investors
Orasis Pharmaceuticals' founders and board of directors
Founder? Claim ProfileOrasis Pharmaceuticals' employee count trend
Orasis Pharmaceuticals has 66 employees as of Sep 26. Here is Orasis Pharmaceuticals's employee count trend over the years:
Uncover Orasis Pharmaceuticals' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Orasis Pharmaceuticals's Competitors and alternates
Top competitors of Orasis Pharmaceuticals include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Orasis Pharmaceuticals, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
3rd | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
4th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
5th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
6th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
7th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
8th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
9th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 71/100 | |
10th | Bluebird Bio 1992, Cambridge (United States), Acquired | Developer of gene therapies for severe genetic and rare diseases | $136M | 71/100 | |
250th | Orasis Pharmaceuticals 2015, Herzliya (Israel), Series D | Developer of reformulated eye drops for the treatment of Presbyopia | $111M | 57/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Orasis Pharmaceuticals's competitors? Click here to see the top ones
Orasis Pharmaceuticals's Investments and acquisitions
Orasis Pharmaceuticals has made no investments or acquisitions yet.
Reports related to Orasis Pharmaceuticals
Here is the latest report on Orasis Pharmaceuticals's sector:
News related to Orasis Pharmaceuticals
Filter this listMedia has covered Orasis Pharmaceuticals for 1 event in last 1 year, It was about company updates.
•
Orasis Launches Qlosi Starter Packs to Expand Access for Presbyopia TreatmentEyewire•Nov 14, 2025•Orasis Pharmaceuticals
•
•
Israeli Startup Orasis Pharmaceuticals Develops Innovative Treatment for Presbyopia (Age-Related Farsightedness)CAESARS INTERACTIVE ENTERTAINMENT (UK) LIMITED•Oct 11, 2024•Orasis Pharmaceuticals
•
•
Orasis snags $78M to launch presbyopia eye drops more than a year after FDA approvalEndPoints News•Oct 08, 2024•Orasis Pharmaceuticals
•
•
•
•
•
Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of PresbyopiaPR Newswire•Apr 21, 2022•Orasis Pharmaceuticals
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Orasis Pharmaceuticals
Explore our recently published companies
- Onirika - Italy based, 2017 founded, Unfunded company
- The Place for Children with Autism - Chicago based, 2016 founded, Unfunded company
- ToolSphare - Pakistan based, 2026 founded, Unfunded company
- Ervon Technology - Mumbai based, 2023 founded, Unfunded company
- Jensmart - Wilmington based, Unfunded company
- NX Shoji - Minato City based, 1964 founded, Unfunded company
